Search results for "Vein occlusion"

showing 10 items of 44 documents

Arteriovenöse Dissektion (AVD) bei retinalen Venolenastverschlüssen

2009

BACKGROUND: The aim of this study is to report on arteriovenous sheathotomy in branch retinal vein occlusion (BRVO) with a long-term follow-up and examine the visual field effects of this surgical approach. PATIENTS AND METHODS: In a clinical trial 36 eyes with branch retinal vein occlusion (22 eyes with ischaemia, 14 eyes with chronic macular oedema) underwent surgical decompression accompanied by peeling of the membrana limitans interna after prior isovolemic haemodilution for 3 months had been unsuccessfull. RESULTS: All eyes showed a significant reduction of macular oedema 3 months after surgery. During follow-up (median: 26.4 months) visual acuity increased in 24 / 36 eyes and was stab…

medicine.medical_specialtyRetinaVisual acuitygenetic structuresDecompressionbusiness.industrymedicine.diseaseeye diseasesSurgeryVisual fieldOphthalmologymedicine.anatomical_structuremedicineBranch retinal vein occlusionsense organsmedicine.symptombusinessVitreous baseRetinal holeOptic discKlinische Monatsblätter für Augenheilkunde
researchProduct

Retinal vein occlusion: current treatment.

2010

Retinal vein occlusion (RVO) is a pathology noted for more than 150 years. Although a lot has been written on the matter, it is still a frequent condition with multifactorial etiopathogenesis with many unclear aspects. The RVO pathogenesis has varied systemic and local implications that make it difficult to elaborate treatment guidelines. The management of the patient with RVO is very complex and a multidisciplinary approach is required in order to identify and correct the associated risk factors. Laser therapy remains the gold standard in RVO, but only modest functional improvement has been shown in branch retinal occlusion forms. Multicenter studies of intravitreal drugs present them as a…

medicine.medical_specialtyRetinal VeinPegaptanibAngiogenesis Inhibitorschemistry.chemical_compoundCentral retinal vein occlusionOcclusionRetinal Vein OcclusionmedicineHumansIntensive care medicineGlucocorticoidsLaser CoagulationVascular diseasebusiness.industryRetinalGeneral Medicinemedicine.diseaseCombined Modality TherapySensory SystemsSurgeryOphthalmologychemistryIntravitreal InjectionsRanibizumabbusinessRetinopathymedicine.drugOphthalmologica. Journal international d'ophtalmologie. International journal of ophthalmology. Zeitschrift fur Augenheilkunde
researchProduct

Safety and Efficacy of Ranibizumab in Macular Edema following Retinal Vein Occlusion.

2013

Macular edema is the leading cause of visual impairment in patients with retinal vein occlusion. Limited improvements may be obtained with laser photocoagulation or intravitreal triamcinolone. However, according to the data provided by randomized clinical trials, intravitreal injections of ranibizumab (Lucentis; Genentech, South San Francisco, CA) constitute a new effective and safe option for the management of these vision-threatening diseases. The aim of the present review is to summarize the clinical evidence of ranibizumab for macular edema due to retinal vein occlusions.

medicine.medical_specialtyRetinal Veingenetic structuresReviewlaw.inventionRandomized controlled triallcsh:OphthalmologylawOphthalmologyOcclusionMedicineIn patientranibizumabMacular edemaIntravitreal triamcinolonemacular edemabusiness.industrymedicine.diseaseVEGFeye diseasesantiangiogenic therapylcsh:RE1-994retinal vein occlusionRetinal vein occlusionsRanibizumabbusinessBiomedical engineeringmedicine.drugOphthalmology and eye diseases
researchProduct

Intravitreal pegaptanib for refractory macular edema secondary to retinal vein occlusion

2011

Patricia Udaondo1,2, Salvador Garcia-Delpech1,3, David Salom1,3, Maria Garcia-Pous1,3, Manuel Diaz-Llopis1,31Nuevo Hospital Universitario y Politecnico La Fe, Valencia, Spain; 2University Cardenal Herrera CEU, Valencia, Spain; 3Faculty of Medicine, University of Valencia, Valencia, SpainPurpose: To assess the efficacy of intravitreal Pegaptanib sodium (Macugen®) injection in the management of refractory macular edema secondary to branch retinal vein occlusion.Methods: This is a prospective, nonrandomized, interventional case series. Five eyes of five patients with macular edema refractory to either bevacizumab or triamcinolone were treated with intravitreal injection of Pegaptanib s…

medicine.medical_specialtyVisual acuityRetinal VeinTriamcinolone acetonideBevacizumabgenetic structuresBCVAPegaptanibCase Reportpegaptanib sodiumOphthalmologymedicinePegaptanib SodiumMacular edemaBRVObusiness.industryClinical OphthalmologyRE1-994medicine.diseaseeye diseasesSurgeryOphthalmologyMacugen®Branch retinal vein occlusionsense organsmedicine.symptombusinessmedicine.drug
researchProduct

Intravitreal Pegaptanib in Ischemic CRVO Refractory Exudative Macular Detachment

2012

Abstract Recent literature data reported evidence of the visual and/or anatomical benefits of all clinically available anti-VEGF drugs for the treatment of macular edema (ME) following Central Retinal Vein Occlusion (CRVO), up to 1-year followup. There are no randomized clinical trial data on anti-VEGF agents in ischemic CRVO-ME and the use of anti-VEGF agents to treat this condition. A 73-year old caucasian man, with a medical history of diabetes and systemic hypertension and an ophthalmic history of ischemic CRVO with cystoid macular edema was referred to our division on January 2011. The ophthalmic examination showed in right eye a visual acuity of 20/2000, a C2N1 cataract and an exudati…

medicine.medical_specialtyVisual acuitygenetic structuresPegaptanibIntravitreal pegaptanibCentral retinal vein occlusionOphthalmologymedicinePegaptanib SodiumExudative macular detachment; Central retinal vein occlusion; Intravitreal pegaptanibMedical historyMacular edemamedicine.diagnostic_testSettore MED/30 - Malattie Apparato Visivobusiness.industryCentral retinal vein occlusionExudative macular detachmentmedicine.diseaseFluorescein angiographyeye diseasesSurgerysense organsmedicine.symptomRanibizumabbusinessmedicine.drugJournal of Clinical & Experimental Ophthalmology
researchProduct

Management of macular edema due to branch retinal vein occlusion with intravitreal injections of pegaptanib sodium

2009

Purpose To evaluate the efficacy of Pegaptanib Sodium as single therapy for macular edema due to non-ischemic branch retinal vein occlusion. Methods In this uncontrolled prospective pilot study 17 patients have been included with non-ischemic branch retinal vein occlusion. All of them showed macular edema in the OCT with central foveal thickness higher than 350 microns (mean, 541 +/- 140) and decrease in visual acuity lower than 0,5 Snellen ETDRS charts notation (mean, 0,16+/-0,14). After an initial injection of Pegaptanib Sodium evaluations were programmed every 5 weeks and further retreatments were developed in cases with macular thickness higher than 300 microns. No other therapies were …

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industryFoveal thicknessGeneral Medicinemedicine.diseaseeye diseasesSurgeryOphthalmologyPegaptanib SodiumMedicineBranch retinal vein occlusionsense organsmedicine.symptombusinessMacular edemaActa Ophthalmologica
researchProduct

Nd:YAG-Laserung einer retrohyaloidalen Blutung nach Venenastverschluss

2006

Background A retrohyaloidal haemorrhage can be caused by different underlying diseases. Usually dense haemorrhages are treated by early vitrectomy. We want to report the successful treatment of a retrohyaloidal haemorrhage by means of Nd:YAG laser membranotomy. Materials and methods A 47-year-old man noticed two weeks before presentation a sudden visual loss in the left eye. Visual acuity on the first visit was c. c. 20/32 OD and c. c. 20/400 ex. OS. Dilated fundus examination of the left eye showed multiple intraretinal haemorrhages in the superior periphery and a dense retrohyaloidal haemorrhage over the macula. Anamnestic risk factors for ocular bleeding were systemic hypertension in con…

medicine.medical_specialtyVisual acuitygenetic structuresbusiness.industrymedicine.medical_treatmentVitrectomyAnterior surfaceSudden visual lossDilated fundus examinationmedicine.diseaseeye diseasesSurgeryOphthalmologyNd:YAG lasermedicinesense organsEpiretinal membranemedicine.symptomRetinal branch vein occlusionbusinessKlinische Monatsblätter für Augenheilkunde
researchProduct

Acquired Ocular Toxoplasmosis

1991

A 31-year-old man exhibited a bilateral deterioration of vision over the course of 1 week. The right fundus showed the picture of a central vein occlusion, and the left of a disseminated choroiditis. Indirect immunofluorescent testing indicated a titer of 1:2048 for toxoplasmosis. Fluorescein angiography revealed a hitherto unique picture of isolated choroidal occlusions but neither a central vein occlusion nor a disseminated choroiditis. Using only specific antitoxoplasmotic therapy, the patient regained full visual acuity on both sides. The original findings and the results of a 14-year follow-up are presented.

medicine.medical_specialtyVisual acuitymedicine.diagnostic_testbusiness.industryEye diseaseFundus (eye)Fluorescein angiographymedicine.diseaseeye diseasesVein occlusionToxoplasmosisSurgeryOphthalmologychemistry.chemical_compoundchemistryOphthalmologyAngiographymedicinesense organsFluoresceinmedicine.symptombusinessOphthalmology
researchProduct

Temporal Profile of Gene Induction After Venous Ischemia and Effects of Spreading Depression

2004

Occlusion of two adjacent cortical veins is followed by a widespread reduction of rCBF and the occurrence of small infarcts, which become larger if spreading depression (SD) occurs. The infarct matures over time with TUNEL-positive cells seen in the penumbra up to 4 days after vein occlusion. Caspase inhibition with zVAD.fmk reduces infarct size. Here, the time course of gene expression in the penumbra is compared to that induced by SD alone.

medicine.medical_specialtybiologybusiness.industryPenumbraIschemiaGene inductionmedicine.diseaseVein occlusionCortical spreading depressionInternal medicineAnesthesiaOcclusionGene expressioncardiovascular systemCardiologybiology.proteinMedicinebusinessCaspase
researchProduct

Neuronal immunoreactivity for mannose-binding lectin after venous occlusion-induced focal cerebral ischemia in rats

2012

Abstract A recent research reveals that complement activation exacerbates cerebral infarction. However, involvement of the lectin pathway, (the third complement activation pathway) in cerebral ischemia is not well studied. In this study, we investigated the appearance of mannose-binding lectin (MBL) in ischemic brain tissue. Male Wistar rats ( n  = 25) were divided into three groups: untreated control, sham, and vein occlusion (VO). Rats in the VO group had two adjacent photochemically occluded cortical veins. Regional cerebral blood flow (rCBF) was measured in the sham and VO groups. Rats were perfusion-fixed at 72 h in the sham group and at 3, 24, and 72 h after inducing ischemia in the V…

medicine.medical_specialtybusiness.industryCerebral infarctionGeneral NeuroscienceIschemiachemical and pharmacologic phenomenamedicine.diseaseVein occlusionComplement systemPsychiatry and Mental healthEndocrinologyCerebral blood flowInternal medicineLectin pathwayImmunologymedicineImmunohistochemistryNeurology (clinical)businessMannan-binding lectinNeurology, Psychiatry and Brain Research
researchProduct